Use of co-releasing compounds for the manufacture of a medicament for the treatment of inflammatory diseases
CA 2475209 A1 · Owner: Alfama - Investigacao E Desenvolvimento De Produtos Farmaceuticos Lda. · Inventors: Royo, Beatriz; Fernandes, Ana Cristina; Romao, Carlos
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Several classes of in vivo carbon monoxide-releasing compounds are useful for the treatment and/or prevention of diseases such as chronic inflammatory, e.g. rheumatoid arthritis and of diseases with a strong inflammatory component, such as atherosclerosis, stroke coronary disease, and Alzheimers , disease. The in vivo carbon monoxide-releasing compounds can be attached to known drug vectors and/or known anti-inflammatory drugs such as aspirin.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed February 3, 2003. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended February 3, 2023.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by February 3, 2025.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.